3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
1251
Specimen Handling
867
Carboplatin
816
Magnetic Resonance Spectroscopy
803
Cyclophosphamide
794
Cisplatin
715
Nivolumab
646
Paclitaxel
623
Radiotherapy
564
Gemcitabine
562
Biopsy
529
Bevacizumab
468
Dexamethasone
433
fludarabine
404
Docetaxel
370
venetoclax
365
Oxaliplatin
362
Fluorouracil
352
Capecitabine
350
atezolizumab
341
Rituximab
326
durvalumab
326
Doxorubicin
313
Radiosurgery
305
Pemetrexed
302
Drug Therapy
294
Standard of Care
292
Ipilimumab
289
Etoposide
279
Radiation
277
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
bexmarilimab
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled
NCT07460986
2026-03-10
BEXAR
MedSIR
Phase 1/2
Not yet recruiting
278 enrolled